Immunome, Inc. (NASDAQ:IMNM) Poised For Near-Term Momentum After Regulatory Filing And Pipeline Advances
![]() |
Immunome shows strengthened liquidity and advancing clinical milestones that support a bullish near-term technical backdrop while fundamentals reflect continued R&D investment and negative operating results. WMDST values the stock as under-valued. |








